Introduction
Paroxysmal nocturnal hemoglobinuria (PNH) arises in an hematopoietic stem cell due to an acquired somatic mutation in the phosphatidylinositol glycan class A (PIG-A) gene. 1, 2 Affected progeny cells are incapable of biosynthesis of the glycosylphosphatidylinositol (GPI)-anchor and lack from their surface all GPI-anchored proteins (GPI-AP). Intravascular hemolysis results from failure of complement inactivation by CD59, missing from the surface of GPI-AP-deficient erythrocytes. 3 However, the pathogenesis of other cardinal features of PNH, such as the propensity to venous thrombosis and bone marrow failure, remains unclear. 3, 4 Moreover, expansion of a PNH clone is not the simple result of the mutational event, as PIG-A-mutant cells exist in small numbers in normal individuals, and murine 'knock-out' animals do not show inexorable proliferation of aberrant clones. Clinical overlap with immunemediated aplastic anemia (AA) has suggested the hypothesis of an autoimmune pathophysiology of PNH. In support, association with particular HLA-antigens (HLA-DR1501) 5 and abnormalities of the immune system such as oligoclonality of the TCR repertoire have been described in PNH. 6, 7 The TCR repertoire is physiologically extremely diverse, as a result of somatic V-(D)-J rearrangement and the contribution of nongermline N nucleotides; 8 dominance of a few TCRs over the heterogeneous repertoire is typical of oligoclonal T-cell immune response. 9 TCR clonality may be assessed by flow cytometric analysis of Vb usage 10 and by molecular studies, 11, 12 including size-distribution analysis and sequencing of the highly variable complementarity determining region 3 (CDR3; the site of peptide binding), giving a unique signature of a T-cell clone or clonotype. Our group has systematically studied cellular immune responses in different hematologic diseases characterized by bone marrow failure. We initially reported T-cell oligoclonality by CDR3 spectratyping in AA and PNH; 7 more recently, we identified patient-specific cytotoxic T-cells (CTL) clones in these syndromes. 13, 14 Such clones were immunodominant in vivo and correlated with disease activity; thus they likely have a pathogenic role. Similar findings were also demonstrated in myelodysplastic (MDS) patients (Plasilova et al, Blood 2002; 101: 167; abstract #625). 15 Large granular lymphocytic (LGL) leukemia is a condition characterized by expansion of morphologically typical lymphocytes displaying an effector phenotype; 16 TCR repertoire analysis using flow cytometry and molecular assays is helpful in identifying and characterizing LGL clones and their clonotypes. 17 LGL syndrome is often clinically associated with mono-or multilineage cytopenias, and a single case of PNH with concomitant LGL leukemia has been reported. 18 These observations raise the question whether clonal T-cell expansion, bone marrow failure, and eventually expansion of a GPI-AP-deficient clone may be expression of an analogous pathogenic mechanism.
In the current study, we analyzed a large cohort of PNH patients for the presence of T-cell responses in vivo. Clonal T cells could provide evidence for an immune pathophysiology for the bone marrow impairment in PNH and for a relationship among different bone marrow failure syndromes. We compared results in PNH patients with our previous findings in AA and LGL leukemia, aiming to describe the pathogenic boundary among these different marrow failure conditions.
Patients and methods

Patients and samples
A total of 24 consecutive patients with PNH were included in the study; peripheral blood (PB) was obtained according to standard protocol for venipuncture approved by the Institutional Review Board of our institution and with informed consent. The presence of a PNH clone was determined by flow cytometry if 41% of GPI-AP-deficient circulating neutrophils, defined by negativity for surface staining for CD66b and CD16, were present as a distinct population of CD15 þ cells. 19 Patients were categorized as hemolytic PNH or AA/PNH based on clinical evidence of marked hemolysis (elevated LDH, plasma and urine hemoglobin, reticulocytosis) or a history or manifestations of marrow failure 20 (platelet counts o50 000/ml, neutrophil counts o1000/ml), respectively. At the time of sampling, none of the patients were actively infected.
Vb cytometry
Fresh PB was stained with a mixture of four monoclonal antibodies (mAbs), including a specific anti-TCR-Vb mAb (FITCor PE-conjugated) and an anti-CD28 mAb (PE-or FITCconjugated), and then counterstained for CD4 (ECD) and CD8 (PeCy5). 7 After a 20 min incubation at room temperature, erythrocytes were lysed, the remaining cells were fixed with a Q-prep apparatus (Beckman-Coulter). Then they were further analyzed by a Coulter XL flow cytometer equipped with an Epics Elite software. A four color protocol was used: the individual percentage contribution of each of the 22 Vb-subfamilies mAb was determined as previously described. 7 All mAbs were obtained from Beckman-Coulter (Fullerton, CA, USA), except anti-Vb 6.7 (Endogen, Woburn, MA, USA); mAbs anti-CD55 and anti-CD59 were used for analysis of GPI-anchored proteins (Pharmigen, San Diego, CA, USA).
Polymerase chain reaction (PCR) and CDR3 size distribution analysis CD4 þ and CD8 þ T-cell subsets were obtained from PB mononuclear cells by positive or negative selection after direct labeling with anti-CD4 (or -CD8) mAb conjugated with magnetic microbeads (MACS; Miltenyi Biotec, Auburn, CA, USA). 7 Total RNA was extracted (TRIzol, GIBCO-BRL, Bethesda, MA, USA), and first strand cDNA synthesis was performed (GIBCO-BRL) starting from 0.5 mg of RNA. CDR3 fragments were amplified by PCR using an antisense TCR constant-b (Cb) common primer and one of 22 Vb-family-specific sense primers, as described. 7, 11, 12 A fluorescence-based ABI310 DNA sequencer (Applied Biosystem, Foster City, CA, USA) was used to resolve the composition of Vb-CDR3 pools.
TCR-b CDR3 cloning and sequencing
PCR-amplified CDR3 fragments of expected size were purified from agarose gel (Qiagen Gel Extraction Kit, Quiagen, Valencia, CA, USA) and directly ligated into a pCR s
2.1-TOPO
s cloning vector using the TOPO-TA cloning system (Invitrogen Corp., Carlsbad, CA, USA). 21 Transformation into bacteria was performed according to the manufacturer's instructions. Single colonies were randomly selected and grown; inserted fragments were sequenced from plasmid DNA using an ABI PRISM BigDye Terminator v3.0 Cycle Sequencing Ready Reaction Kit and an ABI 3100 Genetic Analyzer (Applied Biosystem). Sequences were analyzed with Chromas software (Technelysium Pty Ltd, Helensvale, Australia) for Jb usage and compared to the human TCR genes database (the International ImMunoGeneTics Database, University of Montpellier, France; http://imgt. cines.fr:8104/home.html). Unique CDR3 sequences were determined, and amino-acid translations were deducted; repetitive CDR3 sequences were identified, and their frequency within the Vb-specific CDR3 pool was determined to identify dominance of single clones.
Results
TCR-Vb distribution by flow cytometry in PNH patients
Using mAbs specific to individual TCR-Vb subsets and flow cytometry, we determined the distribution of TCR-Vb families in 10 hemolytic PNH cases and 14 AA/PNH patients. The individual contribution of each Vb-subset to the CD4 þ and CD8 þ T-cell pools was initially established in healthy individuals in order to establish normal ranges. In contrast to the relatively constant Vb-distribution in normals, most patients showed a very different pattern, with marked over-and underrepresentation of individual Vb subfamilies ( Figure 1 ). Both CD4 þ and CD8 þ populations harbored some Vb expansions, defined as contributions higher than mean þ 2 standard deviations of normal controls; no common pattern of Vb usage could be identified among different subjects. As we previously reported in AA, over-representation of a particular Vb as more prominent in effector T cells (defined by dim CD28 expression); as a result, expanded subfamilies appeared to be largely CD28 dim T cells. No differences in Vb subfamily expansions between patients with hemolytic PNH and those with aplasia were seen; on average, two or three Vb-subfamilies were expanded in each patient (Figure 1 ).
PNH with concomitant LGL-leukemia
One patient of our cohort (PNH#10) presented very distinctive features: he showed an absolute lymphocytosis (7500 cells/ml), which appeared on the blood smear mostly due to the presence of large granular lymphocytes. Flow cytometry demonstrated the presence of a population of CD8 þ T cells of effector phenotype (CD56 þ , CD16 þ , CD57 þ ), consistent with a coexisting lymphoproliferative disorder; clonal TCR-g gene rearrangement on routine clinical testing confirmed the diagnosis of concomitant LGL-leukemia. At the time of testing, the patient harbored a major PNH clone within both granulocytes and red cells (65 and 55%, respectively), without hemolysis; this patient had also prior history of aplastic anemia. When we analyzed the Vbdistribution of circulating lymphocytes, the almost total contribution of a single Vb-family (TCR-Vb3) to this homogeneous CD8 þ /CD28 dim population was demonstrated. By molecular methods, the Vb-specific mRNA CDR3 pool was amplified by RT-PCR using a fluorescent Cb-primer, and resolution on agarose gel of the amplicon (spectratyping analysis) documented the presence of a single dominant peak, strongly suggesting the presence of a clonal population. Cloning and sequencing of amplified product showed a unique highly dominant CDR3 sequence, confirming clonality; the patient subsequently developed a fatal nonhematologic malignancy.
LGL-like expansions in PNH
We retrospectively analyzed PNH patient samples for extremely large relative expansions of a single Vb-subset; an arbitrary threshold of 25% of the total ab þ /CD8 þ /CD28 dim lymphocytes was utilized. The rationale of this value is based on the observation that such extreme expansions were observed only in frank LGL and are uncommon even in conditions where skewing and clonality of the T-cell repertoire can be demonstrated, as in AA. Within the remaining 23 cases, three patients fulfilling these stringent criteria were identified, and selected for further molecular study of TCR-b genes; their clinical features are summarized in Table 1 . Patient #12 was a 31-year-old female who had been diagnosed as having hemolytic PNH 9 years earlier, initially manifested by a postpartum cerebral vein thrombosis. She presented to us with intravascular hemolytic anemia and relatively preserved white cell and platelet counts. Bone marrow examination showed erythroid hypercellularity (60-70%) with some megaloblastic changes, without other evidence of dysplasia in any hematopoietic lineages or lymphoid cell infiltration. Flow cytometry documented the lack of GPI-AP on 75% of red cells and 93% of neutrophils, confirming the diagnosis of PNH. TCR-Vb analysis of her T cells showed the presence of a Vb2 clone accounting for 30% of her total CD8 T cells, and 49% of effector (CD28 dim ) CD8 T cells. CD8 þ /Vb2 þ T lymphocytes were also found expressing typical effector markers, such as CD56, CD57, and CD16;
LGL morphology was apparent on the blood smear. Similar to the majority of T cells in this patient, the Vb2/CD8 clone express CD55 and CD59 normally, with a very few lymphocytes (o1%) lacking GPI-AP on their surface. Cells from this patient were analyzed periodically over the course of 2 years; during that time she showed a progressive increase in the clonal Vb2 T-cell population to 41 and 62% of her total and effector CD8 lymphocytes, respectively.
The second patient (PNH #31) was a 36-year-old woman with a diagnosis of hypoproliferative PNH since 1991; her clinical course was characterized by severe trilineage cytopenia. She had received immunosuppressive treatment with antithymocyte globulin (ATG) with good clinical response; red cell and ) ; ANC: absolute neutrophil count/ml; Ret: reticulocytes Â 1000/ml; Plt: platelets Â 1000/ml; Ly: lymphocytes/ml; LGL: large granular lymphocytes/ml (as determined by morphology); GPI-er: % of GPI-AP-deficient erythrocytes; GPI-gr: % of GPI-AP-deficient granulocytes; LDH: lactate dehydrogenase (UI/l); Bil: bilirubin (g/dl); TCR-g: TCR-g rearrangement by routine analysis; NA: not available.
platelets transfusions could be discontinued but she remained severely neutropenic. At the time of her first TCR analysis, in 2001, 27% of her red cells and 84% of granulocytes displayed the PNH phenotype, and hemolysis was present. Her bone marrow was hypercellular, with adequate representation and maturation of all lineages and without morphologic abnormalities; multiple prominent lymphoid collections were present in nonparatrabecolar locations. By TCR flow analysis, a large population of CD8 þ /Vb8 þ T cell was identified (28 and 36% of total and effector CD8 lymphocytes, respectively); an LGL subpopulation was observed by flow (CD3 þ , CD8 þ , CD56 þ , CD577, CD167) as well as by morphology (75% of circulating lymphocytes) and confirmed by routine TCR g-genes rearrangement, which showed the presence of a clonal T-cell population.
In this patient, a further TCR analysis performed in 2003 showed a moderate increase of clonal Vb8T cells. The third patient (PNH #9) was 61 years old and had presented with hemolytic anemia but adequate leukocytes and platelets counts. Her marrow biopsy was hypercellular, with predominance of megaloblastic erythroid forms, slightly decreased myeloid maturation, normal megakaryocytes, and no lymphoid infiltration. Flow cytometry demonstrated 73% of red cells and 81% of granulocytes lacking GPI-AP. TCR analysis showed predominant usage of Vb22, with 26% of total and 33% of effector CD8 T cells bearing this Vb. On the blood smear, half of the circulating lymphocytes were large cells with abundant cytoplasm and azurophilic granules.
Molecular analysis of LGL-like expansions in PNH patients
Vb-specific mRNA CDR3 pools were amplified by RT-PCR starting from total CD8 þ T cells. By immunoscope, predominance of one CDR3 length peak was observed in all samples; amplicons derived from reverse gene amplification were cloned in bacteria, and DNAs from multiple randomly selected bacterial colonies were sequenced to determine the CDR3 sequence -the unique CDR3 clonotype. CDR3 sequences were compared, and identical sequences were sought. All four patients showed a single, highly redundant CDR3 sequence accounting for more than 60% of the total repertoire ( Figure 2 ). Combining this relative high frequency of CDR3 clonotype with overexpression of the particular Vbfamily, there was an absolute dominance of a unique CTL cell clone. Patient-specific clonotypes were compared among the cases and to our database of AA-and LGL-specific CDR3 sequences, but neither identical sequences nor common aminoacid motifs were identified. Discussion TCR oligoclonality has been described in PNH 6, 7 and has been inferred to reflect an underlying antigen-driven immune response. Such responses have also been reported in AA 7, 13 and MDS (Plasilova et al, Blood 2002; 101: 167; abstract #625) 15 -all syndromes of bone marrow failure. TCR clonality is a hallmark of LGL-leukemia, 18, 22 which is also characterized by a specific immunophenotype and morphology of expanded clones. 16 In the current study, we confirm our recent findings using a different series of PNH patients; 14 in this PNH cohort, we have observed a surprisingly high frequency of major LGLlike expansions within CD8 effector cells. To date, only one instance of PNH associated with a typical LGL-disease has been published as a case report. 18 In our previous series of 45 LGL patients analyzed by TCR clonality, only one patient showed evidence of GPI-AP-deficient granulocyte or red cells by flow cytometry. 17 Here, we document that four of 24 PNH patients harbored major T-cell clonal expansions, one of them developing clinically typical LGL disease.
Clonal T-cell expansions were initially suspected by Vb flow cytometry and then characterized in detail by a high-resolution molecular analysis of the TCR-b-CDR3 repertoire, including sequencing of the specific dominant clonotype. Comparison of dominant CDR3 sequences to clonotypes, previously identified in AA, MDS, and LGL patients, did not show apparent structural homology, and any interpretation of the immune specificity of CTL clones was therefore not possible. However, given HLA heterogeneity, similarity among triggering antigen(s) cannot be excluded; these still unknown antigens could be normally present on normal hematopoietic progenitors but upregulated or aberrantly expressed on target cells. Expanded clones shared with typical LGL proliferations the effector phenotype as well as a characteristic morphology, and TCR-g-gene rearrangement confirmed the presence of clonal populations. Thus, subclinical
LGL-like clonal CTL responses may be more frequently encountered than can be extrapolated based on routine clinical testing, implying the diagnostic criteria for LGL-processes may need to be further refined. 22 Although LGL disease is defined as an abnormal expansion of LGL with an effector phenotype, LGL proliferations represent a complex spectrum consisting of different clinical entities, from reactive LGL expansion to aggressive LGL leukemia;
16 transient physiologic immune reaction or true malignancy may lead to completely different clinical pictures. 23 In the molecular era, the original definition based on large expansion of morphologically distinctive lymphocytes has been revised, and even relatively low LGL counts are now compatible with a specific diagnosis. 22 The relevance of clonality is still debated, as not all LGL processes are monoclonal, and clonality does not necessarily equate to malignancy in the context of T-cell biology. The current hypothesis is that LGL disease derives at least initially from antigen-driven expansion of CTL clones, which eventually acquire additional biological features determining particular clinical manifestations. 23 For an example, impairment of apoptotic pathways or activation of proliferation genes may lead to increased survival and autonomous (antigen-independent) growth typical of classic indolent LGL lymphocytosis. 24 This model is also supported by evidence of nonrandom evolution of dominant CTL clones in LGL, as a result of antigen-driven selection (Wlodarski et al, Blood 2003; 103: 601; abstract #2218). 25 Immunologic specificities of the expanded clone likely also account for the frequent association with organ-specific autoimmune manifestations. 26, 27 In our observations, bone marrow failure and LGL-expansions appear to reflect the poles of the same pathophysiologic process rather than the association of two independent diseases. In this view, an exaggerated CTL-driven immune response would account for marrow failure and cytopenia in aplastic as well as in LGL patients, as supported by the presence of cytotoxic T cells with effector phenotype in both conditions. 28 Destruction of hematopoietic cells by immune mechanisms has been demonstrated in AA; 13, 21, 29, 30 furthermore, clones of GPI-APdeficient cells are present in most AA patients 31, 32 and, conversely, marrow failure is a hallmark of PNH. 4 It appears unlikely that an intrinsic difference of PIG-A mutated clone is sufficient to account for selective expansion of a PNH clone. 3, [33] [34] [35] The four hemolytic PNH patients reported here may be extreme examples in the setting of hematopoietic failure of an immune pathophysiology that may be present in a more subtle form in all PNH and possibly also in AA. In a continuum of antigen-driven clonal responses in immune-mediated bone marrow failure syndromes, 23 these hemolytic PNH patients would be very close to the pole represented by LGL-leukemia.
LGL may provide an immune environment that might selectively favor expansion of a pre-exisiting PNH clone. Possibly, the rescue of hematopoiesis provided by PNH clonal escape from immune attack results in a more subtle disease, allowing more prominent T-cell clonal expansion than would be seen with a more acute and globally destructive process as in severe AA. The lack of specific immunosuppressive treatment in PNH may also contribute to development of larger LGL populations; the continued expansion of clonal CTL in two patients longitudinally studied is consistent with this hypothesis. Our data are compatible with a pathogenic model of PNH in which extrinsic factors confer a selective advantage to GPI-APdeficient hematopoiesis. 3 Variables determining the relative manifestations of marrow failure vs T-cell proliferation likely include the nature of the specific antigen(s) driving the immune pathophysiology, the efficiency of hematopoietic target cell killing, and biological features of the pathogenic T-cell clone providing for growth or survival advantages. Additional intrinsic features of mutant PNH clone may themselves also affect hematopoietic function.
We conclude that expansion of putative pathogenic T-cell clones can be identified in PNH patients, as previously shown in other bone marrow failure syndromes. Within PNH as a diagnostic category, a spectrum may also exist determined in part by the escape of PIG-A mutant clone(s) from immune attack and destruction, possibly leading to different clinical manifestations. However, no major biological difference emerges between aplastic and hemolytic PNH, even if major LGL-like expansions were identified only in the latter condition. Analysis of Vb-distributions within specific lymphocyte subpopulations (such as the CD28 dim or CD56 þ T-cell pool), followed by molecular study of hypervariable regions of the TCR, may be a powerful tool for a more sensitive identification of CTL clonal expansions not detectable by routine techniques. Beyond their utility as disease markers in true T-cell malignancies, further molecular and functional characterization of such CTL clones will clarify their role in normal as well as aberrant immune responses and provide a better understanding of the pathophysiologic boundary between different marrow failure conditions.
